August 3, 2022
August 3, 2022
Article describes Enteris’ strengths and scalability in working with highly potent active pharmaceutical ingredients Boonton, NJ, August 03, 2022 — Enteris BioPharma, Inc., a biotechnology company developing […]
July 14, 2022
July 14, 2022
Boonton, NJ, July 14, 2022 — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
June 13, 2022
June 13, 2022
Data suggest that oral formulations of leuprolide developed utilizing Enteris’ Peptelligence® platform successfully deliver meaningful circulating drug concentrations and achieve hormonal suppressive effects which are comparable to parenteral administration.
June 7, 2022
June 7, 2022
Facilities and processes key to protecting workers and the environment, the paper in Drug Development & Delivery says Boonton, NJ, June 7, 2022 — Enteris BioPharma, Inc., […]
May 26, 2022
May 26, 2022
Boonton, NJ, May 26, 2022 — Enteris BioPharma, Inc. gave plush animals a dose of personality as they created a dozen stuffed teddy bears for Ronald McDonald […]
May 4, 2022
May 4, 2022
Boonton, NJ, May 4, 2022 — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
April 12, 2022
April 12, 2022
Boonton, NJ, April 12, 2022 — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
KNOWLEDGE CENTER
Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.
LEARN MOREKNOWLEDGE CENTER
Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.
LEARN MORE
